Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon

Clinical trial NCT02356809 · UNKNOWN

Trial details

NCT number: NCT02356809
Sponsor: Artgen Biotech
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Secondary Raynaud's Phenomenon

Start date: 2015-03-01
Primary completion: 2015-03-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.